Hepatitis B virus reactivation with a rituximab-containing regimen

Yutaka Tsutsumi, Yoshiya Yamamoto, Shinichi Ito, Hiroyuki Ohigashi, Souichi Shiratori, Hirohito Naruse, Takanori Teshima

Abstract
Rituximab is currently used not only in the treatment of B-cell lymphoma but also for various other diseases, including autoimmune diseases, post-transplant graft vs host disease, and rejection following kidney transplants. Due to rituximab's widespread use, great progress has been made regarding research into complications that arise from its use, one of the most serious being the reactivation of hepatitis B virus (HBV), and efforts continue to establish guidelines for preventive treatment against this occurrence. This report discusses preventive measures against rituximab-induced HBV reactivation and future objectives.

Key words: Rituximab; Hepatitis B virus; Reactivation; Nucleoside analog; Non-Hodgkin's lymphoma

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: For preventive measures against hepatitis B virus (HBV) reactivation during rituximab treatment, hepatitis B surface (HBs) antigen positive and Hbc antibody positive/HBs antibody negative patients are subject to prophylactic treatment with nucleoside analogs. During rituximab treatment, the HBV-DNA levels of patients who are Hbc antibody positive (HBs antibody positive or negative) are ideally monitored with PCR once a month. If the PCR results are positive, the administration of nucleoside analogs is initiated. However, since monitoring HBV-DNA levels is expensive, it might be preferable to follow the HBs antibodies instead. Due to wide differences in the insurance situations in each country, including the follow-up intervals, further research must determine ideal follow-up intervals. However, no standard exists for the timing of this treatment's termination. For HBs antigen negative patients who also receive nucleoside analog treatment, it
will be necessary in the future to evaluate the possibility of switching to a vaccine when a patient becomes HBs antibody positive.

Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, Teshima T. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 2015;7(21):2344-2351 Available from: URL: http://www.wjgnet.com/1948-5182/full/v7/i21/2344.htm DOI: http://dx.doi.org/10.4254/wjh.v7.i21.2344

INTRODUCTION

Rituximab, which improves the prognosis of CD20-positive B-cell lymphoma, is generally indispensable for the treatment of B-cell lymphoma[1-3]. Rituximab inhibits the production of various antibodies by targeting CD20 positive B-cells and is effective for a range of conditions, including diopathic thrombocytopenic purpura, chronic rheumatoid arthritis, multiple sclerosis, and cryoglobulinemic vasculitis with applications to other diseases as well[4-7]. On the other hand, extensive studies have also recently been conducted on rituximab’s side effects, which include reports not only of typical infusion reactions but also various infectious diseases due to its immune suppressive effects: Cytomegalovirus, progressive multifocal leukoencephalopathy, parvovirus infection, and Herpes zoster[8-11]. Although hepatitis B virus (HBV) reactivation has been previously reported to be a complication of chemotherapy[12-16], this phenomenon has drawn greater attention due to reports that argue that the frequency of reactivation is higher in patients treated with rituximab than those who only received chemotherapy[17-24]. The best way to deal with HBV reactivation is to prevent it[25,26]. In this review, we describe the prevention and treatment of HBV reactivation based on previous reports and discuss a summary and future objectives.

Principle of HBV reactivation during rituximab treatment

After HBV infection, HBV-DNA synthesis is initially suppressed by cytokine production from NK and other cells. A subsequent cytotoxic T-cell (CTL) reaction occurs due to the presence of CD8-positive T lymphocytes. Because hepatitis is triggered by CTLs, a time lag likely exists between the HBV infection and the manifestation of hepatitis[27,28]. On the other hand, rituximab induces CD4 lymphopenia[29,30]. In a mouse model, B-cell depletion reduced the number and the fraction of CD4 memory T-cells and impaired immunity against virus infection[31]. A reduction in CD20 Bcells shifted the CD4 effector phenotype to that of enhanced interferon-γ, interleukin (IL)-2, and tumor necrosis factor. Perhaps the depletion of CD20 positive B-cells reduces the production of IL-7 and IL-15, both of which are critical for memory T-cell survival, from monocytes or stromal cells[31]. Furthermore, HBV replication is likely accelerated by the indirect effects of B-cell depletion on immune globulin production. It has been reported that rituximab treatment induces a change in CD8 distribution[30]. This might reduce the number of CD8-positive cells and the subsequent acceleration of HBV replication. Once the number of CD8-positive T-cells recovers, cells are produced that specifically target HBV. However, since memory T-cells are impaired by their reduced numbers, CD8-positive T-cells randomly attack HBV, resulting in severe hepatitis[31].

Rituximab not only affects B-cells but T-cells as well and accelerates HBV replication. This is a primary factor in the induction of HBV replication by the administration of rituximab alone.

Epidemiology of HBV reactivation

When combined with chemotherapy, the HBV reactivation rate during rituximab treatment has been reported to be 20%-55% overall and 3% in hepatitis B surface antigen (HBsAg) negative patients[12-30]. HBV reactivation can be caused by chemotherapy alone. However, rituximab more easily induces HBV reactivation independently upon combined treatment with chemotherapy or steroid treatment[18,26]. The frequency of HBV reactivation is also higher with combination treatments including rituximab compared to chemotherapy alone or a combination chemotherapy and steroid treatment[18,27]. Risk factors for HBV reactivation in patients receiving chemotherapy include being male, lack of HBs antibody, HBs antigen positivity, presence of a precore mutant, HBV-DNA level, anthracycline/steroid use, transplantation, second/third line treatment, youth, and the presence of lymphoma[35,37-39]. However, when rituximab is used, the risk factors for HBV reactivation are narrowed to a lack of HBs antibody, youth, and being male[37]. All the above reports are retrospective analyses of patients who were HBs antigen positive and who therefore were subject to prophylactic nucleoside analog therapy. In the future, patient groups must be identified who tend to experience reactivation even when receiving such therapy.

Many remaining problems must be addressed. One is whether the attending physician performs antibody or DNA tests before initiating chemotherapy or a rituximab/chemotherapy combination. This issue is rather basic; yet a surprising report by Méndez-Navarro et al[40] in 2011 showed that serological screening of HBV is only done in less than 40% of cases before treatment. In some cases, HBV reactivation went undetected because no HBV screening was conducted. Zurawska et al[41] analyzed the effect of HBsAg screening by dividing patients into three groups: screening, non-screening, and only screening of high-risk patients. Their results showed that the group that was screened before treatment had the highest prevention rate of HBV reactivation (10-fold); screening the high-risk patient group was the most cost effective measure. When comparing the screening and non-screening groups, the former was more cost effective. Screening prevents HBV reactivation.

Another problem is the screening method. Some patients were diagnosed as HBe antibody negative
when using the EIA method (AxSYM Assay: Abbott Laboratories, Chiba, Japan, 2005), but they were diagnosed as HBc antibody positive with the CLIA method (Architect Assay: Abbott Laboratories, Chiba, Japan, 2013). Thus, in the past, we overlooked an HBV reactivation risk factor since our treatment was based on AxSYM results. Therefore, reports on HBV reactivation cannot be compared since the results were biased by the screening method. This affects the evaluation of risk factors and prophylactic administration. International standardization of screening methods is needed.

The risk factors for HBV reactivation include being male, lack of HBs antibody, HBs antigen positive, presence of precore mutant, HBV-DNA level, anthracycline/steroid combination therapy, transplantation, second/third line treatments, youth, and the presence of lymphoma; When rituximab is used, the risk factors are narrowed down to a lack of HBs antibody, youth, and being male; Currently, the screening rate for HBV is only 30%-40%; Standardization of screening methods is a future task.

**HBV-DNA mutations**

HBV-DNA mutations must be considered when assessing the potential difficulties in the treatment of HBV using nucleoside analogs. Pelizzari et al.[43] reported that the mutation rate in HBV-DNA with lamivudine is lower than the rate during treatment for hepatitis B. However, in their study, the observation period was short and they analyzed too few cases. Several mutations were reported in HBV reactivated patients. Main of these mutations were developed in immune-active HBsAg regions, such as M103I-L109I-T118K-P120A-Y134H-S143L-D144E-S171F. In other patients, C48G-V96A-G185E-V190A mutations were observed whose function escaped the T-cell-mediated responses for HBV. An N-linked glycosylation site was observed in a major hydrophilic loop in HBV reactivated patients without HBsAg[43]. Compared to treatment with standard chemotherapy with or without rituximab, the mutation rate during the prophylactic treatment of HBV-DNA with lamivudine was approximately 15%-20%. Therefore, this indicates no significant difference in the HBV-DNA mutation rate with lamivudine between the prophylactic and standard HBV hepatitis treatment periods[44,45]. A fatal case was also described in which HBV reactivation was caused by HBV-DNA mutation during R-CHOP treatment, although not at an early stage[46]. Recently, encouraging results have been reported on the effectiveness of entecavir in the prevention of HBV reactivation[47]. Due to the low frequency of the emergence of a resistant HBV strain with entecavir use, this is the first choice for the prophylactic treatment of patients with high viral load or patients who require a long prophylactic treatment period[47].

Lamivudine resistance was induced early when a nucleoside analog such as fludarabine was used with rituximab[48]. Similar reports have been noted for the induction of HBV-DNA mutations by nucleoside analogs when steroids or fludarabine were used with rituximab[49]. Note that the combined use of such purine analogs as fludarabine and cladribine with rituximab tends to induce HBV-DNA mutations. A report on HBV reactivation with bendamustine (an alkylating agent) as well as a nucleoside analog has also been published. However, HBV-DNA mutations with these agents were not evaluated and their effectiveness in this regard remains unknown[50].

With regard to HBV-DNA mutations, entecavir is desirable for prophylactic treatment in the event of HBV reactivation due to its poor ability to induce mutations in HBV-DNA. However, its cost is problematic, and measures must be enacted that are suitable for different countries.

The presence of HBV mutations corresponds to the frequency of the emergence of resistant strains with standard nucleoside analogs. Perhaps HBV mutations will increase with a combination treatment of steroids or anti-cancer drugs such as purine analogs that have a strong immune suppressive effect.

**HBs antigen positive cases**

There is an international consensus that nucleoside analog administration is necessary in HBs antigen positive patients since prophylactic treatment is effective for the prevention of HBV reactivation and reduces mortality in this group[51-53]. Guidelines for each analog are shown in Table 1. When referring to the guideline treatments for HBs antigen positive chronic hepatitis, entecavir use is desirable when the HBV-DNA concentration exceeds 20000 IU/mL, while lamivudine use is adequate if the HBV-DNA concentration falls under 20000 IU/mL. In addition, in HBV-DNA-positive cases, the possible existence of YMDD mutations must be determined beforehand. If such mutations are detected, using tenofovir or the combined use of two nucleoside analogs might become necessary. As mentioned previously, entecavir is more desirable for the prevention of HBV reactivation due to its low induction of resistant strains during treatment. Ideally, it is desirable to start prophylactic treatment two weeks after the administration of nucleoside analogs since the drugs are most effective during this period. However, there is no standard protocol regarding the starting time for treatment since the specific condition of each individual patient often plays a role. In our clinic, steroids are not used on patients who are HBs antigen positive. A fatality was previously observed in a group of patients who were receiving steroid/rituximab combination therapy that caused HBV-DNA mutation and HBV reactivation even though the patient was HBs antigen negative. We believe that the use of steroids should be avoided, at least in HBs antigen positive patients[47].

For HBs antigen positive patients, treatment with nucleoside analogs is necessary to prevent HBV reactivation.

Although from the point of view of preventing drug
HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; ALT: Alanine aminotransferase.

Table 1  Guidelines for chemotherapy or immunosuppressive drug therapy

| AASLD | Subject to preventive treatment if HBsAg positive or anti-HBc positive and HBV-DNA positive. If HBV-DNA concentration is less than 20000 IU or for a shortednted treatment (< 1 yr), lamivudine or telbivudine is desirable. If HBV-DNA concentration exceeds 20000 IU and long-term treatment is necessary, entecavir or tenofovir is desirable. If HBV-DNA concentration remains less than 2000 IU six months after the completion of treatment, the treatment should be discontinued; otherwise treatment shall continue (2009) |
| APASL | There are no guidelines (2005) |
| EASL | HBsAg cases are subject to treatment, and HBV-DNA is measured in these cases, although there is no defined value in which treatment recommendations can be made. Lamivudine is most commonly used; however, it is best used in cases with low HBV-DNA concentration or when resistant strains are less likely to emerge. In high HBV-DNA concentration cases or when there is a high risk of resistance, entecavir is desirable. Careful follow-up of HBV-DNA concentration and liver function is necessary for HBsAg negative, Anti-HBC positive, and HBV-DNA negative cases. Vaccination is recommended in HBV seronegative cases (2009) |
| JAPAN | Subject to nucleoside analog treatment if HBsAg positive or if HBsAg negative, and anti-HBs or HBc positive plus HBV-DNA positive. If HBV-DNA is negative, HBV-DNA is monitored monthly and nucleoside analogs are administered when HBV-DNA becomes positive. Entecavir is recommended as the nucleoside analog. The timing of the termination of the nucleoside analog treatment shall be determined in accordance with the treatment for type B chronic hepatitis if HBsAg is positive. If the patient is anti-HBs or anti-HBc positive, a nucleoside analog is administered for 12 mo after the completion of immunosuppressive therapy or chemotherapy. During this time, nucleoside analog treatment will be discontinued if HBV-DNA is negative and ALT is normal. Patients are closely observed for 12 mo after treatment with nucleoside analogs (2009) |

HBs antibody negative are subjected to prophylactic treatment with nucleoside analogs.

**HBC antibody positive/HBs antigen negative/HBs antibody negative**

The HBC antibody positive/HBs antigen negative serotype is further divided into naive (HBs antibody positive) and occult types (HBs antibody negative). However, since HBV reactivation is often observed in HBc antibody positive/HBs antigen negative cases, it may be preferable to divide HBc antibody positive/HBs antigen negative cases based on whether they are positive or negative for HBs antibodies. For HBc antibody positive patients, perhaps HBV reactivation is induced by rituximab. Although Hui et al. reported a 3%-25% reactivation rate, prophylactic treatment may be desirable since the mortality is relatively high (30%-38%) after reactivation occurs. In 2013, Huang et al. conducted a randomized controlled trial to evaluate the effect of the prophylactic administration of entecavir on the frequency of HBV reactivation in HBC antibody positive patients. In their report, unlike in retrospective analyses, the prophylactic administration of entecavir was the most important factor, at least for HBc antibody positive patients. Furthermore, Seto et al. recently reported frequent reactivation of HBV in patients with 10 mIU/mL HBs antibody prior to rituximab treatment. In HBc antibody positive patients, prophylactic treatment is necessary, at least for those who are antibody negative prior to rituximab treatment (occult type). We believe that the prophylactic administration of a nucleic acid analog is preferable in HBc antibody positive/HBs antigen negative/HBs antibody negative cases.

HBc antibody positivity can cause HBV reactivation. Attention is required since mortality is high after reactivation occurs.

Patients who are both HBc antibody positive and HBs antibody negative are subjected to prophylactic treatment with nucleoside analogs.

**HBC antibody positive/HBs antigen negative/HBs antibody positive**

There are reports of HBV reactivation in HBC-ab negative/HBs-ag positive/HBs-ab positive cases, and reactivation occurred in 6.9% of them. HBV reactivation in HBC antibody negative/HBs antigen negative/HBs antibody positive cases has also been reported (albeit in small numbers), and reactivation was reported in 3.4% of them.

We previously reported decreased HBs and HBC antibodies as well as induced reactivation after combination rituximab/chemotherapy in HBs antibody positive patients. HBs antibody in particular decreased in patients with < 300 mIU/mL and disappeared in patients with < 100 mIU/mL after combination therapy with rituximab and chemotherapy. For patients who were originally HBC antibody positive/HBs antibody positive but became HBs antibody negative after continuous treatment with rituximab, perhaps HBV reactivation can be induced by maintenance therapy with rituximab. Therefore, the possibility of HBV reactivation must be evaluated for group receiving maintenance therapy with rituximab. Since a case has been documented in which HBV reactivation occurred even though the patient had an HBs antibody titer of 868 mIU/mL, monthly follow-ups must be conducted during treatment for HBV-DNA positive patients. However, such prophylactic treatment is expensive and HBV reactivation remains a possibility. At present, HBV-DNA follow-up is deemed adequate if the follow-up of HBs and HBC antibodies is extended to once a month. We must identify those who require prophylactic treatment from among HBC antibody positive/HBs antigen negative/HBs antibody positive and HBC antibody negative/HBs antibody positive patients.

Particular attention must be paid to patients with...
< 300 mIU/mL of HBs antibody during maintenance treatment with rituximab since the HBs antibody status might become negative (follow-up of HBs antibody concentration is required).

Since HBV reactivation was reported even in patients with a high HBs antibody titer, HBs antibody follow-up is not sufficient for detecting the occurrence of reactivation. Monthly follow-up for the presence of HBV-DNA is necessary during treatment.

**Administration of nucleoside analogs upon HBV reactivation**

As for the prophylactic administration to prevent HBV reactivation, low HBV drug resistance is desirable. Although different guidelines exist, 0.5 mg of entecavir might be desirable with regard to both effectiveness and minimizing drug resistance. Depending on the cost of the drug and individual financial circumstances, 100 mg of lamivudine is also acceptable, although drug resistant strains are induced more easily. In this case, various guidelines are helpful in the selection of appropriate prophylactic drugs [51-53]. If HBV reactivation occurs, the patient should be dealt with based on the treatment of acute hepatitis B. Although the first choice for treatment is 0.5 or 100 mg of lamivudine, interferon is usually employed as well for acute hepatitis since nucleoside analogs do not take effect immediately upon HBV reactivation. However, in the case of HBV reactivation, interferon is difficult to apply since reactivation occurs after rituximab or chemotherapy treatment and prolonged bone marrow suppression might occur. Interferon’s administration is also undesirable because it can exacerbate liver damage [61]. In our clinic, liver protective drugs (glycyrrhizic and ursodeoxycholic acids) are used together, although they might remain insufficient. If resistance develops to entecavir or lamivudine, 10 mg of adefovir or 200 mg of tenofovir should be used [52,53,61,62]. However, great caution is required since switching treatment drugs may induce further HBV drug resistance [63]. Tenofovir has been reported to be effective for lamivudine as well as adefovir resistant HBV strains [64-66].

We must evaluate whether to discontinue nucleoside analog administration in patients receiving those drugs that promote HBV reactivation. Since HBs antibody might become negative during rituximab treatment, discontinuation should be considered after the treatment’s completion. An additional problem exists with regard to determining the duration of the discontinuation period. Cases of HBV reactivation even after long periods of discontinuation have been documented. For example, even after HBs antibody became temporarily positive, it disappeared later and HBV reactivation was induced [66,67]. If nucleoside analog treatment is given to HBs antibody negative patients who later become antibody positive, such treatment can be discontinued [53]. On the other hand, HBV vaccination is unable to suppress HBV reactivation [68]. If rituximab is administered continuously, HBs antibody may not be induced even after HBV vaccination. It is necessary to evaluate not only the induction of HBs antibody after HBV vaccination but also diseases that are appropriate for the discontinuation of nucleoside analog treatment. Based on the above discussion, Figure 1 shows the modified guidelines from

![Figure 1 The review is summarized as schematics. The treatment direction described here is based on the assumption that all patients are screened in advance. HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus.](image-url)
the Ministry of Health, Labour and Welfare.

Although entecavir is the first choice for prophylactic treatment against HBV reactivation, the decision to use it might also be based on financial conditions, and the guidelines should be referred to when selecting the appropriate drug.

When lamivudine resistance emerges, the treatment drug should be switched to adefovir or tenofovir.

Since nucleoside analogs do not take effect immediately upon HBV reactivation, combination treatment with interferon should be considered. However, bone marrow suppression must be considered for patients with hematological disorders.

The discontinuation of nucleoside analogs must be considered in the future. For HBs antigen negative patients, the discontinuation of nucleoside analog treatment may be possible through a vaccine.

CONCLUSION

Regarding the prevention of HBV reactivation, based on results from clinical studies conducted so far, not only HBs antigen positive patients but also those who are HBs antibody negative/HBc antibody positive might be eligible for prophylactic treatment. By employing combination rituximab/chemotherapy, safer treatment for malignant lymphomas is possible. On the other hand, HBV reactivation during maintenance therapy with rituximab must be considered. The discontinuation of nucleoside analog treatment may be possible through combined administration of an HBV vaccine in patients who are receiving nucleoside analogs as a preventive treatment against HBV reactivation (primarily for antibody negative cases).

REFERENCES

1 Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457-2466 [PMID: 7552629]
2 Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997; 90: 2188-2195 [PMID: 9310469]
3 Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1997; 15: 3266-3274 [PMID: 9336364]
4 Khelfa M, Charles-Nelson A, Fain O, Terriou L, Viallard JF, Cheze S, Graveleau J, Slama B, Audia S, Ebbro M, Le Guenno G, Cliquennois M, Salles G, Bonmati C, Teillet F, Galicier L, Hot A, Lambotte O, Lefrere F, Sacko S, Kengue DK, Bierling P, Roudot-Thoraval F, Michel M, Godeau B. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood 2014; 124: 3228-3236 [PMID: 25293768 DOI: 10.1182/blood-2014-06-582346]
5 Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-2581 [PMID: 15201414 DOI: 10.1056/NEJMoa035234]
6 Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One 2013; 8: e66308 [PMID: 23843952 DOI: 10.1371/journal.pone.0066308]
7 Petraco A, Rigacci L, Caimi P, Colangradi S, Romagnoli P, Vizzutti F, Arena U, Giannini C, Monti M, Montalto P, Matteucci-Cerin M, Bosi A, Laffi G, Zignego AL. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinaemia and severe liver disease. Blood 2010; 116: 335-342 [PMID: 20308664 DOI: 10.1182/blood-2009-11-253483]
8 Bermeñdez A, Marco F, Conde E, Mazo R, Recio M, Zubizarreta A. Fatal viral scarcella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000; 85: 894-895 [PMID: 10942955]
9 Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000; 96: 1184-1186 [PMID: 10910942]
10 Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001; 345: 1000 [PMID: 11575282 DOI: 10.1056/NEJM200109273451315]
11 Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE, Imrit K, Preti RA. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and post-transplantation rituximab. Blood 2002; 99: 1486-1488 [PMID: 11830505 DOI: 10.1182/blood.V99.4.1486]
12 Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and chronic leukaemia associated with a diagnosis and therapeutic challenge. Lancet 1975; 2: 526-530 [PMID: 51345]
13 Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Miestich KC, Young RC, Costa J. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447-449 [PMID: 7065560 DOI: 10.13726/0003-4819-96-4-447]
14 Thung SN, Gerber MA, Klon F, Gilbert H. Massive hepatic necrosis after chemotherapy with rituximab in a patient with B virus infection. Carcinogenesis 1985; 145: 1313-1314 [PMID: 4015284 DOI: 10.1001/arch1985.00336070195034]
15 Lai CY, Lai CL, Lin HJ, Lok AS, Liang RH, Wu PC, Chan TK, Todd D. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989; 73: 911-917 [PMID: 2926092]
16 Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu EK. Hepatitis B infection in patients with lymphomas. Hematol Oncol 1990; 8: 261-270 [PMID: 1701155 DOI: 10.1002/hon.2900080504]
17 Tsutsumi Y, Kamamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masazui N. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005; 4: 599-608 [PMID: 15934864 DOI: 10.1517/14740338.4.3.599]
18 Tsutsumi Y, Shimetzu A, Hashino S, Tanaka J, Chika K, Masazui N, Kobayashi H, Kurosawa M, Iwasaki H, Moriko A, Asaka M, Imamura M. Analysis of reactivation of hepatitis B virus in patients with lymphomas. Ann Hematol 2009; 88: 375-377 [PMID: 18726097 DOI: 10.1007/s00277-008-0585-6]
19 Skrabs C, Miller C, Agis H, Mannhalter C, jäger U. Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia 2002; 16: 1884-1886 [PMID: 12200717 DOI: 10.1038/sj.leu.2402567]
20 Westhoff TF, Jochimsen F, Schmittel A, Stoffler-Meilecke M, Schafer JH, Zidek W, Gerlich WH, Thiel E. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930 [PMID: 12903732 DOI: 10.1182/blood-2003-05-1403]
21 Derwite I, Hofer D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69 [PMID: 11187122 DOI: 10.1056/NEJM200101043440120]

Tsutsumi Y et al. HBV reactivation with rituximab therapy
Tsuchiya Y et al. HBV reactivation with rituximab therapy

Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant liversclerosis after fludarabine and rituximab therapy: case report. Ann Hematol 2001; 80: 549-552 [PMID: 11669307 DOI: 10.1007/s002770010346]

Jäger G, Neunmueller P, Breitenecker R, Höfler G, Quenemberger F, Linkesw C, Sill H. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Eur J Haematol 2002; 69: 21-26 [PMID: 12270058 DOI: 10.1046/j.1014-6609.2002.01692.x]

Yang SH, Kuo SH. Reactivation of hepatitis B virus during treatment of a patient with follicular lymphoma. Ann Hematol 2008; 87: 325-327 [PMID: 17926271 DOI: 10.1007/s00277-007-0396-1]

Tsuchiya Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, Asaka M, Imamura M, Masuazi N. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 2004; 83: 58-60 [PMID: 14513286 DOI: 10.1007/s00277-003-0748-4]

Tsuchiya Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, Kanamori H, Tanaka J, Asaka M, Imamura M, Masuazi N. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004; 45: 627-629 [PMID: 15160930 DOI: 10.1080/10428190310151923]

Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D, Mulleman D, Goupille P, Ribourtout B, Watier H, Ogasawara R, Miyashita N, Tanaka J, Asaka M, Johnson PJ. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311 [PMID: 15054446 DOI: 10.1053/j.bj.2004.11.009]

Kim HY, Kim W. Chemotherapy-related reactivation of hepatitis B infection: updates in 2013. World J Gastroenterol 2014; 20: 14581-14588 [PMID: 25356022 DOI: 10.3748/wjg.v20.i40.14581]

Méndez-Navarro J, Carey KE, Zheng H, Barlow LW, Jing Y, Lin W, Zhao H, Shao RX, McAfee SL, Chung RT. Hepatitis B virus screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 2011; 31: 330-339 [PMID: 20738779 DOI: 10.1111/j.1478-3231.2010.02323.x]

Zurawski U, Hicks LK, Wu G, Bell CM, Krahm M, Chan K, Feld JJ. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012; 30: 3167-3173 [PMID: 22711851 DOI: 10.1002/jco.20115.47]

Pelizari AM, Motta M, Cariani E, Turconi P, Borlenghi E, Rossi G. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J 2004; 5: 325-328 [PMID: 15297849 DOI: 10.1086/0.260396]

Salpini R, Colagrossi L, Bellocci MC, Surdo M, Becker C, Alteri C, Aragri M, Ricciardi A, Armenia D, Pollicita M, Di Santo F, Carioti L, Louzoun Y, Mastroianni CM, Lichtner M, Paoloni M, Esposito M, D’Amore C, Marrone A, Marignani M, Sarreccchia C, Sarmati L, Andreoni M, Angelico M, Verheyen J, Pero PNF, Svicher V. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression. Hepatology 2015; 61: 823-833 [PMID: 25418031 DOI: 10.1002/hep.27604]

Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-861 [PMID: 14999707 DOI: 10.1002/hep.20110]

Win LL, Panis J, Shah H, Feld JJ, Wong DK. Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due to Rapid Emergence M204 Mutations. Case Reports Hepatol 2013; 2013: 454897 [PMID: 25374716 DOI: 10.1155/2013/454897]

Huang YH, Hsiao LT, Hong YC, Chiu TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tseng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772 [PMID: 23775967 DOI: 10.1200/JCO.2012.48.5938]

Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin’s lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 2003; 88: 1296-1303 [PMID: 14607759]

Miyagawa M, Minami M, Fuji K, Sendo R, Mori K, Shimizu D, Nakajima T, Yasaki K, Itoh Y, Tanwaki M, Okanoue T, Yoshikawa T. Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab. J Med Virol 2008; 80: 2069-2078 [PMID: 19040281 DOI: 10.1002/jmv.21311]

Tsuchiya Y, Ogasawara R, Miyashita N, Tanaka J, Asaka M, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68 [PMID: 16831590 DOI: 10.1053/j.gastro.2006.01.015]

Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KL, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticoagulant therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611 [PMID: 19075267 DOI: 10.1200/JCO.2008.18.0182]

Yeo W, Zee B, Zhong S, Chan PK, Wong W, Ho WM, Lam KC, Johnson PJ. Reactivation of hepatitis B virus replication in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311 [PMID: 15054446 DOI: 10.1053/j.bj.2004.11.009]
Tsutsumi Y et al. HBV reactivation with rituximab therapy

Imamura M. HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine. *Int J Hematol* 2012; **95**: 588-591 [PMID: 22419099 DOI: 10.1007/s12185-012-1050-9]

Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007; **45**: 507-539 [PMID: 17256718 DOI: 10.1002/hep.21513]

Liu YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. *Liver Int* 2005; **25**: 472-489 [PMID: 15910483 DOI: 10.1111/j.1478-3231.2005.00113.x]

European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. *J Hepatol* 2009; **50**: 227-242 [PMID: 19054588 DOI: 10.1016/j.jhep.2008.10.001]

Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, Iodice V, Sagnelli C, Stanzione M, Capoluongo N, Pasquale G, Sagnelli E. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. *J Med Virol* 2011; **83**: 1909-1916 [PMID: 21915865 DOI: 10.1002/jmv.21219]

Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, Zou S. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study. *Eur J Haematol* 2010; **85**: 243-250 [PMID: 20491883 DOI: 10.1111/j.1600-0609.2010.01474.x]

Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. *World J Hepatol* 2014; **6**: 384-393 [PMID: 25018849 DOI: 10.4254/wjh.v6i6.3849]

Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Le AK, Lai CL, Kwong YL, Yuen MF. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. *J Clin Oncol* 2014; **32**: 3736-3743 [PMID: 25287829]

Tsutsumi Y, Ogasawara R, Kaminara Y, Ito S, Yamamoto Y, Tanaka J, Asaka M, Imamura M. Rituximab administration and reactivation of HBV. *Hepat Res Treat* 2010; **7**: 182067 [PMID: 21188195]

Tsutsumi Y, Yamamoto Y, Tanaka J, Asaka M, Imamura M, Masazui N. Prevention of hepatitis B virus reactivation under rituximab therapy. *Immunotherapy* 2009; **1**: 1053-1061 [PMID: 20635919 DOI: 10.2217/imt.09.59]

Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T. Hepatitis B virus reactivation with rituximab-containing regimen. *World J Hepatol* 2013; **5**: 612-620 [PMID: 24303089 DOI: 10.4254/wjh.v5.i11.612]

Ababkhal F, Eliesy H, AIOMair A, Alghamdi MY, Alalwan A, AlMasri N, AL-Hamoudi W. SASLT practice guidelines for the management of hepatitis B virus. *Saudi J Gastroenterol* 2014; **20**: 5-25 [PMID: 24496154 DOI: 10.4103/1139-3767.126311]

Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S, Kleszewski KS, Thiry A, Rose RE, Colombo RJ, Hindes RG. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. *Gastroenterology* 2005; **129**: 1198-1209 [PMID: 16230074]

Fung SK, Andreone P, Han SH, Rajender Reddy K, Regev A, Keefle EB, Hussain M, Cursaro C, Richtmyer P, Marrero JA, Lok AS. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. *J Hepatol* 2005; **43**: 937-943 [PMID: 1616522]

Peters MG, Hahn HW, Hu, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray DF, Sullivan M, Kleber K, Ebabahimi R, Xiong S, Brossart CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. *Gastroenterology* 2004; **126**: 91-101 [PMID: 14699491 DOI: 10.1053/j.gastro.2003.10.051]

Pérez-Roldán F, González-Carro P, Villafañez-Garcia MC. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. *N Engl J Med* 2005; **352**: 310-311 [PMID: 15659742 DOI: 10.1056/NEJM200501203520324]

Tillmann HL, Wedemeyer H, Manns MP. Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation. *J Hepatol* 2003; **39** Suppl 1: S206-S211 [PMID: 14708705]

Dai MS, Chao TY, Kao WY, Shyu RC, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. *Ann Hematol* 2004; **83**: 769-774 [PMID: 15338194]

Awerkiew S, Däumer M, Reiser M, Wend UC, Pfister H, Kaiser R, Willems WR, Gerlich WH. Reactivation of occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. *J Clin Virol* 2007; **38**: 83-86 [PMID: 17134939]
